COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00250640
Recruitment Status : Completed
First Posted : November 8, 2005
Last Update Posted : February 2, 2015
Information provided by (Responsible Party):

Brief Summary:
This is an observational study to monitor the continued effectiveness of Ventavis (inhaled iloprost) in the long-term. The study observes the effects and the safety of Ventavis inhalation therapy over at least 2 years and up to 4 years. A total of 54 patients from around 30 study sites in Europe will be included in the study. This observational study will collect information in patients receiving a medication that is already available on prescription in the participating countries. Ventavis is used to treat moderate cases of primary pulmonary hypertension.

Condition or disease Intervention/treatment
Hypertension, Pulmonary Drug: Iloprost (Ventavis, BAYQ6256)

Layout table for study information
Study Type : Observational
Actual Enrollment : 106 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Open-label, Uncontrolled, Prospective Long-term Observation of Ventavis Inhalation Therapy in the Treatment of Patients With Primary Pulmonary Hypertension up to 4 Years
Study Start Date : April 2005
Actual Primary Completion Date : April 2012
Actual Study Completion Date : July 2012

Group/Cohort Intervention/treatment
Group 1 Drug: Iloprost (Ventavis, BAYQ6256)
The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet

Primary Outcome Measures :
  1. The primary efficacy variable is 6-minute walking distance. Focus will lay on the individual changes (in meters) at Month 3 (after inhalation) compared to the value measured at baseline. [ Time Frame: Month 3 Visit ]

Secondary Outcome Measures :
  1. Relative change in the 6-minutes walking distance (%), as compared to baseline (BL): clinical improvement is defined as an increase of at least 10% vs BL; clinically significant deterioration is defined as a decrease of at least 30% vs BL. [ Time Frame: all scheduled visits (Study period is min. 2 years and max. 4 years) ]
  2. Changes in the NYHA class (to determine the patients' clinical conditions) vs. baseline will be classified into: improved, unchanged and deteriorated. Improvement is a negative difference; deterioration is a NYHA class increase from baseline. [ Time Frame: all scheduled visits (Study period is min. 2 years and max. 4 years) ]
  3. Mortality, defined as all-cause mortality, will be assessed for all patients included in this study. [ Time Frame: all scheduled visits (Study period is min. 2 years and max. 4 years) ]
  4. The safety and tolerability of Ventavis will be assessed by an examination of the adverse event data collected in this study. [ Time Frame: all scheduled visits (Study period is min. 2 years and max. 4 years) ]
  5. Other safety variable [ Time Frame: At all scheduled visits (Study period is min. 2 years and max. 4 years) ]
    Weight, vital signs, findings in PPH-related signs and symptoms, hospitalization because of PPH, incidence of heart and/or lung transplantation

  6. Other safety variables (optional assessment) [ Time Frame: At all scheduled visits (Study period is min. 2 years and max. 4 years) ]
    Chest x-ray, electrocardiogram, findings of heart catheter test, findings of pulmonary function tests, findings of blood gas analyses

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with the disease in scope and the prescription of Ventavis mainly from expert clinics in the participating countries

Inclusion Criteria:

  • The treating physician has chosen Ventavis as a suitable long-term treatment for the patient
  • Patient with primary pulmonary hypertension (i.e. Idiopathic Pulmonary Arterial Hypertension or Familial Pulmonary Arterial Hypertension) and classified as NYHA functional class III (NYHA = New York Heart Association)
  • No prior treatment with Ventavis or other active treatments for primary pulmonary hypertension within 6 weeks of date of study inclusion (unless otherwise advised by Bayer Schering Pharma)

Exclusion Criteria:

  • Any condition that prevents participation in the study, including pregnancy and other contraindications for Ventavis treatment (as listed in the current Ventavis Summary of Product Characteristics and patient package insert)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00250640

Layout table for location information
Brest, France, F-29609
Clamart Cedex, France, 92141
Lille, France, 59037
Lyon Cedex 03, France, 69394
Pessac, France, 33604
Reims, France, 51092
Strasbourg, France, 67091
Vandoeuvre les Nancy Cedex, France, 54500
Donaueschingen, Baden-Württemberg, Germany, 78166
Heidelberg, Baden-Württemberg, Germany, 69120
Heidelberg, Baden-Württemberg, Germany, 69126
Löwenstein, Baden-Württemberg, Germany, 74245
Erlangen, Bayern, Germany, 91054
München, Bayern, Germany, 80336
München, Bayern, Germany, 81377
Regensburg, Bayern, Germany, 93053
Gießen, Hessen, Germany, 35392
Bonn, Nordrhein-Westfalen, Germany, 53105
Essen, Nordrhein-Westfalen, Germany, 45147
Köln, Nordrhein-Westfalen, Germany, 50924
Mönchengladbach, Nordrhein-Westfalen, Germany, 41069
Wuppertal, Nordrhein-Westfalen, Germany, 42283
Homburg/Saar, Saarland, Germany, 66421
Dresden, Sachsen, Germany, 01307
Leipzig, Sachsen, Germany, 04103
Erfurt, Thüringen, Germany, 99089
Berlin, Germany, 12200
Berlin, Germany, 13353
Hamburg, Germany, 20246
Bologna, Italy, 40138
Pavia, Italy, 27100
Pisa, Italy, 56100
Roma, Italy, 00161
Coimbra, Portugal, 3000-075
Lisboa, Portugal, 1150-291
Barcelona, Spain, 08035
Barcelona, Spain, 08036
Córdoba, Spain, 14004
Madrid, Spain, 28041
United Kingdom
Glasgow, United Kingdom, G11 6NT
London, United Kingdom, NW3 2PF
Newcastle upon Tyne, United Kingdom, NE7 7DN
Sheffield, United Kingdom, S10 2JF
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00250640    
Other Study ID Numbers: 91430
308120 ( Other Identifier: Company internal )
First Posted: November 8, 2005    Key Record Dates
Last Update Posted: February 2, 2015
Last Verified: January 2015
Keywords provided by Bayer:
Primary Pulmonary hypertension
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Platelet Aggregation Inhibitors
Vasodilator Agents